🇪🇺 Supemtek® in European Union

EMA authorised Supemtek® on 30 March 2026

Marketing authorisation

EMA — authorised 30 March 2026

  • Application: EMEA/H/C/006674
  • Marketing authorisation holder: Sanofi Winthrop Industrie
  • Local brand name: Supemtek
  • Indication: Supemtek is indicated for active immunisation for the prevention of influenza disease in adults and children from 9 years of age and older. Supemtek should be used in accordance with official recommendations.
  • Status: approved

On 30 March 2026, the European Medicines Agency (EMA) granted marketing authorisation for Supemtek, a vaccine for active immunisation against influenza disease. Supemtek is indicated for use in adults and children aged 9 years and above. The vaccine should be used in accordance with official recommendations.

Read official source →

Other Psychiatry approved in European Union

Frequently asked questions

Is Supemtek® approved in European Union?

Yes. EMA authorised it on 30 March 2026.

Who is the marketing authorisation holder for Supemtek® in European Union?

Sanofi Winthrop Industrie holds the EU marketing authorisation.